Literature DB >> 2731313

A phase II study of vincristine in malignant mesothelioma--a negative report.

G Mårtensson1, S Sörenson.   

Abstract

A total of 23 consecutive, previously untreated patients with radiographically evaluable, malignant pleural mesothelioma were treated in a phase II study with vincristine. Vincristine was given i.v. at a dose of 1.3 mg/m2 once weekly for 4 weeks, then every 2 weeks. No response was observed. The result suggests that vincristine has little or no therapeutic value in the treatment of malignant mesothelioma.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2731313     DOI： 10.1007/bf00263135

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  11 in total

1.  Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.

Authors:  E G Butchart; T Ashcroft; W C Barnsley; M P Holden
Journal:  Thorax       Date:  1976-02       Impact factor: 9.139

Review 2.  Treatment of diffuse malignant mesothelioma: a review.

Authors:  A P Chahinian; J F Holland
Journal:  Mt Sinai J Med       Date:  1978 Jan-Feb

3.  Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients.

Authors:  M R Law; A Gregor; M E Hodson; H J Bloom; M Turner-Warwick
Journal:  Thorax       Date:  1984-04       Impact factor: 9.139

4.  Diagnosis and prognosis in malignant pleural mesothelioma: a prospective study.

Authors:  G Mårtensson; B Hagmar; L Zettergren
Journal:  Eur J Respir Dis       Date:  1984-04

5.  Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma.

Authors:  P G Sørensen; F Bach; E Bork; H H Hansen
Journal:  Cancer Treat Rep       Date:  1985-12

6.  A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma.

Authors:  B M Cantwell; C R Franks; A L Harris
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma.

Authors:  E K Mbidde; S J Harland; A H Calvert; I E Smith
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience.

Authors:  H J Lerner; D A Schoenfeld; A Martin; G Falkson; E Borden
Journal:  Cancer       Date:  1983-12-01       Impact factor: 6.860

9.  Radiation therapy in the management of patients with mesothelioma.

Authors:  W Gordon; K H Antman; J S Greenberger; R R Weichselbaum; J T Chaffey
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982-01       Impact factor: 7.038

10.  Clinicopathologic studies on mesothelioma of the pleura. Differentiated approach to treatment.

Authors:  S Larsson; B M Philipson; L Dernevik; L Zettergren
Journal:  Scand J Thorac Cardiovasc Surg       Date:  1988
View more
  2 in total

Review 1.  Chemotherapy in malignant mesothelioma: a review.

Authors:  A Krarup-Hansen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 2.  Chemotherapy for malignant pleural mesothelioma: past results and recent developments.

Authors:  S Tomek; S Emri; K Krejcy; C Manegold
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.